Kyu Kwang Kim Selected Research

Neoplasms (Cancer)

6/2023	Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.
10/2022	Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic Mass.
1/2022	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors In Vivo.
1/2021	HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.
1/2020	Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines.
1/2020	Role of trypsin and protease-activated receptor-2 in ovarian cancer.
7/2019	Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.
11/2015	Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.
10/2015	Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells.
8/2012	Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kyu Kwang Kim Research Topics

Disease

20	Neoplasms (Cancer) 06/2023 - 02/2009
13	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 05/2008
7	Neuroblastoma 01/2022 - 10/2007
5	Endometrial Neoplasms (Endometrial Cancer) 01/2020 - 07/2011
2	Inflammation (Inflammations) 01/2011 - 09/2009
2	Prostatic Neoplasms (Prostate Cancer) 08/2009 - 05/2008
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2023
1	Colorectal Neoplasms (Colorectal Cancer) 06/2023
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2023
1	Carcinoma (Carcinomatosis) 01/2022
1	Ascites 01/2021
1	Ovarian Epithelial Carcinoma 01/2021
1	Carcinogenesis 01/2020
1	Hypoxia (Hypoxemia) 10/2015
1	Hypercalcemia (Milk Alkali Syndrome) 11/2011
1	Neoplasm Metastasis (Metastasis) 06/2011
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2011
1	Leukemia 02/2011
1	Infections 09/2009
1	Body Weight (Weight, Body) 09/2009
1	Osteoporosis 11/2005
1	Alzheimer Disease (Alzheimer's Disease) 11/2005
1	Neural Tube Defects (Exencephaly) 11/2005
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2005

Drug/Important Bio-Agent (IBA)

5	PlatinumIBA 10/2010 - 05/2008
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2009
4	CopperIBA 10/2015 - 09/2009
3	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2020
3	Cisplatin (Platino)FDA LinkGeneric 07/2019 - 02/2011
3	tetrathiomolybdate (ammonium tetrathiomolybdate)IBA 11/2015 - 04/2012
3	Iron(III)-salopheneIBA 04/2011 - 05/2008
2	ChromatinIBA 06/2023 - 02/2010
2	Vitamin D FDA LinkGeneric 06/2023 - 11/2011
2	Fluorouracil (Carac)FDA LinkGeneric 04/2012 - 02/2011
2	p38 Mitogen-Activated Protein KinasesIBA 04/2012 - 10/2010
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2012 - 02/2010
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2012 - 07/2011
2	Proanthocyanidins (Procyanidins)IBA 01/2012 - 08/2009
2	RKS 262IBA 06/2011 - 02/2011
2	Calcifediol (Calcidiol)FDA Link 10/2010 - 10/2007
2	Cholecalciferol (Vitamin D3)FDA Link 10/2010 - 10/2007
2	IronIBA 02/2010 - 09/2009
2	Organometallic CompoundsIBA 09/2009 - 05/2008
1	Small Interfering RNA (siRNA)IBA 06/2023
1	AntibodiesIBA 06/2023
1	7-dehydrocholesterolIBA 01/2022
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	ArginaseIBA 01/2021
1	CytokinesIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	TrypsinIBA 01/2020
1	Peptide Hydrolases (Proteases)FDA Link 01/2020
1	CytokininsIBA 01/2020
1	PAR-2 ReceptorIBA 01/2020
1	N-(2-chloro-4-pyridyl)-N'-phenylureaIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2019
1	ErbB Receptors (EGF Receptor)IBA 11/2015
1	Oxygen (Dioxygen)IBA 10/2015
1	Transcription Factors (Transcription Factor)IBA 10/2015
1	abietyl-isothiocyanateIBA 08/2012
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 04/2012
1	CaspasesIBA 04/2012
1	FenretinideIBA 04/2012
1	proanthocyanidinIBA 01/2012
1	Insulin Receptor Substrate ProteinsIBA 11/2011
1	Calcitriol (Calcijex)FDA LinkGeneric 11/2011
1	Ergocalciferols (Ergocalciferol)FDA LinkGeneric 11/2011
1	AntioxidantsIBA 07/2011
1	Cytotoxins (Cytolysins)IBA 04/2011
1	sapacitabineIBA 02/2011
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2011
1	CoumarinsIBA 02/2011
1	NifurtimoxIBA 02/2011
1	chungkookjangIBA 01/2011
1	Bromodeoxyuridine (BrdU)IBA 10/2010
1	Deferoxamine (Desferal)FDA LinkGeneric 02/2010
1	Chelating AgentsIBA 02/2010
1	MetalsIBA 02/2010
1	Proto-Oncogene ProteinsIBA 09/2009
1	InterleukinsIBA 09/2009
1	CobaltIBA 09/2009
1	ManganeseIBA 09/2009
1	Carboplatin (JM8)FDA LinkGeneric 08/2009
1	FlavonoidsIBA 08/2009
1	isothiocyanic acidIBA 02/2009
1	Mitogen-Activated Protein KinasesIBA 02/2009
1	ethyl isothiocyanateIBA 05/2008
1	indoleIBA 05/2008
1	7-methyl-indole ethyl isothiocyanateIBA 05/2008
1	HomocysteineIBA 11/2005

Therapy/Procedure

6	Therapeutics 01/2021 - 10/2010
2	Drug Therapy (Chemotherapy) 01/2021 - 07/2019
1	Radiotherapy 06/2023
1	Intraperitoneal Injections 09/2009
1	Aftercare (After-Treatment) 05/2008